10X Genomics

A regional court said certain 10x Genomics' products, including older GEM chips and some Chromium instruments, infringed a "utility model," similar to a patent.

In its first quarter as a public company, the single-cell analysis firm reported $61.2 million in total revenues, beating Wall Street expectations.

10x will pay Becton Dickinson $25 million over four years and the firms have agreed to refrain from engaging in a legal battle on other fronts.

Two banks said they expect shares of 10x Genomics to outperform the market while JP Morgan gave them an Overweight rating and Bank of America a Buy rating.

Researchers from Wellcome Sanger Institute and elsewhere found that the immune landscape of the kidney is zoned to counter dominant immunological challenges.